{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By KATIE THOMAS and CHAD BRAY", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}, {"rank": 2, "role": "reported", "firstname": "Chad", "organization": "", "lastname": "BRAY"}]}, "abstract": "Pfizer, in wake of failed $152 billion merger with Allergan, may break itself apart by end of 2016; some analysts say two smaller companies would be worth more than one big one; Pfizer's options are limited by new rules intended to restrict inversions.", "type_of_material": "News", "word_count": "929", "lead_paragraph": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "pub_date": "2016-04-07T04:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Pfizer Faces Limited Options After Its Dead Deal With Allergan", "print_headline": "Pfizer Weighs Split as Allergan Deal Collapses"}, "snippet": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "multimedia": [{"height": 126, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 407, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "407", "xlarge": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "ALLERGAN INC", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Corporate Taxes", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "7", "is_major": "Y", "value": "Allergan Inc", "name": "organizations"}], "blog": [], "_id": "5704f14c38f0d848959befb0", "source": "The New York Times"}